According to the FDA’s public database, since the start of this year, the agency has issued only two de novo medical device ...

The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to ...

Replacement therapy: may be substituted for the titrated components. Severe renal impairment: titrate slower. ≥75yrs, or hepatic impairment: not for initial use (initially use amlodipine alone ...

Vigabatrin is indicated as monotherapy for children with infantile spasms and as adjunct therapy for adults ... eliminated primarily by renal excretion as an unchanged drug and has an elimination ...

Expert Rev Endocrinol Metab. 2012;7(3):255-257. The future of hormone replacement therapy in hypoparathyroidism can be viewed with optimism, even if we are left with several unanswered questions ...